
Sign up to save your podcasts
Or


Robert Tipp, Chief Investment Strategist at PGIM Fixed Income, on potential Fed rate cuts and current investment outlook. Dr. Phil Chan, CEO of CytoSorbents (NASDAQ: CTSO), discusses the medical issues surrounding the coronavirus threat, and their technology that can treat compromised immune systems. Michael Tiedemann, CEO of Tiedemann Advisors, on how they’re advising clients in the sell-off. Brian Chappatta on his column: "Bond Traders See Fed Facing All-or-Nothing Call." Hosted by Lisa Abramowicz and Paul Sweeney.
See omnystudio.com/listener for privacy information.
By Bloomberg3.8
381381 ratings
Robert Tipp, Chief Investment Strategist at PGIM Fixed Income, on potential Fed rate cuts and current investment outlook. Dr. Phil Chan, CEO of CytoSorbents (NASDAQ: CTSO), discusses the medical issues surrounding the coronavirus threat, and their technology that can treat compromised immune systems. Michael Tiedemann, CEO of Tiedemann Advisors, on how they’re advising clients in the sell-off. Brian Chappatta on his column: "Bond Traders See Fed Facing All-or-Nothing Call." Hosted by Lisa Abramowicz and Paul Sweeney.
See omnystudio.com/listener for privacy information.

976 Listeners

1,168 Listeners

2,184 Listeners

424 Listeners

970 Listeners

196 Listeners

1,039 Listeners

188 Listeners

70 Listeners

1,308 Listeners

64 Listeners

78 Listeners

30 Listeners

60 Listeners

5 Listeners

58 Listeners

233 Listeners

232 Listeners

67 Listeners

84 Listeners

77 Listeners

76 Listeners

87 Listeners

399 Listeners

18 Listeners

13 Listeners

7 Listeners

2 Listeners

115 Listeners

23 Listeners